HyperTET

Indicated For

tetanus prophylaxis following injury, active tetanus treatment

About This Medication

# Hypermunes Patient Assistance Program Patient Guide: How to Get HyperTET at Low or No Cost HyperTET (tetanus immune globulin [human]) is a vital medication used to prevent tetanus in people who have wounds and inadequate prior vaccination or in those with tetanus exposure. The **Hypermunes Patient Assistance Program** from **Grifols Therapeutics LLC** helps eligible uninsured patients get HyperTET at low or no cost by providing the medication free if you meet income, residency, and other criteria[1][2][4]. ## About HyperTET **HyperTET** is a human tetanus immune globulin that provides passive immunity against tetanus, a serious bacterial infection caused by *Clostridium tetani*. It's typically given as an intramuscular injection for post-exposure prophylaxis in patients with tetanus-prone wounds who haven't completed a primary vaccination series or whose booster is not up to date. The diagnosis and dosing must match the FDA-approved label, as confirmed by your doctor[1][2]. This treatment is crucial because tetanus can lead to muscle spasms, lockjaw, and life-threatening complications if not addressed promptly. Always consult your healthcare provider for personalized advice on its use. ## Who Qualifies for the Program? To qualify for the Hypermunes Patient Assistance Program, you must meet **all** these key requirements: - Be a **US citizen or resident** living in the US, Puerto Rico, or other US territories. - Be under the care of a **US-licensed prescriber** with an established US practice. - Have **no private health insurance** covering HyperTET; patients with **Medicare, Medicaid (including spend-downs), Tricare, VA benefits**, or other federal programs are **not eligible**[1][2][4]. - Provide **proof of income** showing your annual gross income is **250% of the Federal Poverty Level (FPL) or less**. If over 250% FPL, you'll be denied[1][2][4]. - Have a **diagnosis and dosing** consistent with the FDA label[1][2]. - Submit the application **within 90 days** of the product administration date[1]. Proof of residency (like a driver's license or utility bill) isn't always needed but may be requested during an audit[2]. ## Income Eligibility Breakdown The program uses **250% of the Federal Poverty Level (FPL)** as the cutoff for annual gross income. FPL guidelines are updated yearly by the US Department of Health and Human Services. Here's a table with 2026 estimates based on the 2025 guidelines (check HHS.gov for exact current figures, as they adjust for household size and location): | Household Size | 100% FPL | 250% FPL (Eligibility Cutoff) | |----------------|----------|-------------------------------| | 1 (Individual) | $15,060 | **$37,650** | | 2 (Couple) | $20,440 | **$51,100** | | 3 | $25,820 | **$64,550** | | 4 | $31,200 | **$78,000** | *Add ~$5,380 per additional person for 100% FPL (multiply by 2.5 for 250%). Alaska and Hawaii have higher levels. Use gross income before taxes. Provide documents like W-2, tax returns (1040 series), pay stubs + tax return, IRS transcript, Social Security award letter, or unemployment letter[1]. No specific household size thresholds beyond FPL calculation; all income proof is required regardless.*[1][2][4] ## Insurance Requirements You **must be completely uninsured** for HyperTET. **Federally funded programs** like Medicare (including Part D), Medicaid, Tricare, and VA are exclusions—no exceptions[1][2][4]. If you have any private insurance, even if it doesn't cover this drug, you likely won't qualify. Patient certification on the form confirms no coverage and financial need[1]. ## Step-by-Step Application Process 1. **Get Prescribed**: Ask your US-licensed doctor to confirm HyperTET is appropriate and matches FDA labeling. They'll need to provide their info, DEA, state license, and NPI[1][3]. 2. **Download the Form**: Find the Hypermunes Patient Assistance Program application (printable or editable PDF) from Grifols resources, like hyperrab.com or hyperhepb.com sites[1][2][6]. 3. **Gather Documents**: - **Proof of income** (see examples above)[1]. - **Proof of residency** if requested (driver's license, utility bill)[2]. - **Prescriber details** and diagnosis info[1]. 4. **Complete and Sign**: Fill patient, physician, and product sections. Patient certifies no insurance and financial hardship; authorize data use[1]. 5. **Submit**: Use multiple methods—mail, fax, or electronic as available. Physician signature required. Apply within 90 days of administration[1][3]. Contact Grifols for submission details (phone may be 1-833-504-9983 based on similar programs)[7]. 6. **Wait for Approval**: Up to 30 days of product upon approval from receipt[1]. ## Timeline and Delivery Processing time isn't specified, but approval provides product for **up to 30 days** from application receipt[1]. Applications must be received **no later than 90 days post-administration**[1]. Once approved, HyperTET is **shipped to the patient or physician's office**[program details]. Act quickly, as funding is limited[5]. ## Alternatives if Denied or Ineligible - **Hospital Charity Care**: Check your hospital's policy at ncha.org/community-benefit/[5]. - **State Programs**: For example, NC residents may qualify via local health departments if <100% FPL, no insurance, NC resident (affidavit needed)[5]. - **Other Biologics PAPs**: Imogam (Sanofi, 866-801-5655), KEDRAB (866-234-3732), or HyperRAB (Grifols, 1-833-504-9983)[7]. No biosimilars listed for HyperTET. - **RxAssist.org**: Search for matches[3][4]. - **Extra Help for Medicare**: If Medicare-eligible and low-income, apply for LIS first[10]. If denied due to income >250% FPL or insurance, explore copay cards or generic options if available (none noted). ## Important Disclaimer This guide is for informational purposes based on available program details as of 2026 and is **not medical or legal advice**. Eligibility can change; always verify with Grifols directly. Program funding is limited and not guaranteed. Consult your doctor for treatment decisions. Grifols may audit applications. FPL figures are estimates—use official HHS tables. (Word count: 1028)

Program information last verified: March 30, 2026